Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisRaoul Herbrecht, Ben de Pauw, Patricia Ribaud et al.|New England Journal of Medicine|2002Cited by 3.3k
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal InfectionsJohn R. Perfect, Elizabeth M. Johnson, Kieren A. Marr et al.|Clinical Infectious Diseases|2003Cited by 680
Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patientsRichard P. Wenzel, A Marciniak, A. Del Favero et al.|Journal of Antimicrobial Chemotherapy|2005Cited by 66
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised PatientsRosemary A. Barnes, Johan Maertens, Michal Kantecki et al.|Clinical Therapeutics|2015Cited by 27